We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva Submits BLA to FDA for Migraine Candidate Fremanezumab
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd (TEVA - Free Report) announced the submission of a biologics license application (“BLA”) to the FDA seeking approval for its monoclonal antibody candidate, fremanezumab, as a preventive treatment for migraine.
The BLA submission was supported by positive data from two phase III studies under HALO program, which evaluated the candidate in patients with episodic migraine ("EM") and chronic migraine ("CM").
Fremanezumab was subcutaneously administered once a month for two months (quarterly dose regimen), either in high (675mg) or low doses (225 mg, monthly dose regimen) in the study on CM patients. The data demonstrated statistically significant reduction in the number of monthly headache days when treated with fremanezumabcompared to a placebo. The study also met its secondary endpoints and showed significant improvement over placebo.
Data from the study on EM patients showed that patients who were treated with monthly as well as quarterly dosing regimens of fremanezumab experienced clinically and statistically significant improvements in monthly average number of migraine days and 12 pre-specified analyses.
Given the limited treatment options, fremanezumab represents significant commercial potential. According to Teva’s press release, more than a billion people suffer from migraine across the world including 38 million in the United States.
We remind investors that the BLA from Amgen, Inc. (AMGN - Free Report) and partner Novartis AG (NVS - Free Report) for approval of their CGRP receptor, erenumab, for the prevention of migraine was accepted by the FDA in July. Eli Lilly & Company (LLY - Free Report) is also planning to file for FDA approval of its investigational migraine drug, galcanezumab, in the second half of the year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Teva Submits BLA to FDA for Migraine Candidate Fremanezumab
Teva Pharmaceutical Industries Ltd (TEVA - Free Report) announced the submission of a biologics license application (“BLA”) to the FDA seeking approval for its monoclonal antibody candidate, fremanezumab, as a preventive treatment for migraine.
The BLA submission was supported by positive data from two phase III studies under HALO program, which evaluated the candidate in patients with episodic migraine ("EM") and chronic migraine ("CM").
Fremanezumab was subcutaneously administered once a month for two months (quarterly dose regimen), either in high (675mg) or low doses (225 mg, monthly dose regimen) in the study on CM patients. The data demonstrated statistically significant reduction in the number of monthly headache days when treated with fremanezumabcompared to a placebo. The study also met its secondary endpoints and showed significant improvement over placebo.
Data from the study on EM patients showed that patients who were treated with monthly as well as quarterly dosing regimens of fremanezumab experienced clinically and statistically significant improvements in monthly average number of migraine days and 12 pre-specified analyses.
Given the limited treatment options, fremanezumab represents significant commercial potential. According to Teva’s press release, more than a billion people suffer from migraine across the world including 38 million in the United States.
We remind investors that the BLA from Amgen, Inc. (AMGN - Free Report) and partner Novartis AG (NVS - Free Report) for approval of their CGRP receptor, erenumab, for the prevention of migraine was accepted by the FDA in July. Eli Lilly & Company (LLY - Free Report) is also planning to file for FDA approval of its investigational migraine drug, galcanezumab, in the second half of the year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>